Immunocore Holdings plc (FRA:6YG)

Market Cap	1.40B -4.6%
Revenue (ttm)	323.52M +28.1%
Net Income	-24.91M
EPS	-0.50
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	82
Open	28.00
Previous Close	28.00
Day's Range	27.20 - 28.00
52-Week Range	20.80 - 35.60
Beta	n/a
RSI	49.10
Earnings Date	Feb 25, 2026

About Immunocore Holdings

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 493
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6YG

Financial Performance

In 2024, Immunocore Holdings's revenue was $310.20 million, an increase of 24.37% compared to the previous year's $249.43 million. Losses were -$51.09 million, -7.60% less than in 2023.

Financial numbers in USD